Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Alain VergnenègreSpanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group

Abstract

The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal growth factor receptor gene (EGFR)-mutated advanced-stage non-small cell lung cancer (NSCLC) is poorly documented. We therefore conducted a cost-effectiveness analysis of first-line treatment with erlotinib versus standard chemotherapy in European patients with advanced-stage EGFR-mutated NSCLC who were enrolled in the European Erlotinib versus Chemotherapy trial. The European Erlotinib versus Chemotherapy study was a multicenter, open-label, randomized phase III trial performed mainly in Spain, France, and Italy. We based our economic analysis on clinical data and data on resource consumption (drugs, drug administration, adverse events, and second-line treatments) collected during this trial. Utility values were derived from the literature. Incremental cost-effectiveness ratios were calculated for the first-line treatment phase and for the overall strategy from the perspective of the three participating countries. Sensitivity analyses were performed by selecting the main cost drivers. Compared with standard first-line chemotherapy, the first-line treatment with erlotinib was cost saving (€7807, €17,311, and €19,364 for Spain, Italy and France, ...Continue Reading

References

Jun 15, 2007·Current Medical Research and Opinion·Christos ChouaidAlain Vergnenegre
Mar 4, 2009·PharmacoEconomics·Christos ChouaidAlain Vergnenegre
Nov 10, 2010·Health Technology Assessment : HTA·T BrownC Proudlove
Jan 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M HorganN B Leighl
Jun 11, 2011·The European Respiratory Journal·I BorgetUNKNOWN ERMETIC Collaborative Group
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jun 15, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Alain VergnenegreChristos Chouaid
Jun 22, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christos ChouaidPaul L R Mitchell
Sep 3, 2013·Current Treatment Options in Oncology·Thomas E Stinchcombe
Feb 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandjar DjalalovNatasha B Leighl
Apr 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W E E EberhardtUNKNOWN Panel Members
Sep 28, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jie TingLeslie Wilson

❮ Previous
Next ❯

Citations

Jun 6, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Alain Vergnenègre, Christos Chouaïd
Mar 7, 2019·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Cuc Thi Thu NguyenIolanda Grappasonni
May 2, 2016·The European Respiratory Journal·Jordi RemonBenjamin Besse
Sep 5, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Vera Hirsh, Jaspal Singh
Oct 30, 2018·JCO Precision Oncology·Ibiayi Dagogo-JackJochen K Lennerz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.